Ahead of an FDA advisory panel meeting Wednesday, FDA reviewers recommended the approval of Merck & Co.'s experimental blood-clot drug Zontivity, or vorapaxar, for prevention of stroke, cardiac arrest and cardiac-related death in patients who recently had a heart attack. The recommendation was based on "robustly positive" data from the TRA 2P trial.

Related Summaries